AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1911016 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.15‐0.3 mg kg‐1)
Number of subjects: 16
Study 1911016 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 16
Study 1911016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6211999 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg alcuronium
Number of subjects: 50
Study 6211999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg pancuronium
Number of subjects: 50
Study 6211999 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg bw Sch
Number of subjects: 50
Study 6211999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg bw lignocaine
Number of subjects: 50
Study 6211999 — intervention group
Group type: COMPARATOR
Intervention: no pretreatment
Number of subjects: 50
Study 30793259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 127
Study 30793259 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study 27841838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided bilateral intercostal nerve blocks (UG-ICNBs)
Number of subjects: 62
Study 27841838 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 62
Study 26099755 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with adjunctive intrathecal morphine (0.1 mg)
Number of subjects: 50
Study 26099755 — intervention group
Group type: COMPARATOR
Intervention: Continuous lumbar plexus blockade
Number of subjects: 50
Study 24732169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Kinesio taping-compression treatment, performed 3 times a week for 4 weeks
Number of subjects: 130
Study 24732169 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (sham KT)
Number of subjects: 130
Study 24732169 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 130
Study 22729718 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular clips
Number of subjects: 491
Study 22729718 — intervention group
Group type: COMPARATOR
Intervention: Ligatures
Number of subjects: 491
Study 19479599 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoradiotherapy (TRT; RT plus hyperthermia)
Number of subjects: 6
Study 19479599 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 6
Study 17330578 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy with retractor released every 15 minutes (Group B)
Number of subjects: 60
Study 17330578 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrodiscectomy with retractor released every 15 minutes (Group D)
Number of subjects: 60
Study 17330578 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy with retractor never released (Group A)
Number of subjects: 60
Study 17330578 — intervention group
Group type: COMPARATOR
Intervention: Macrodiscectomy with retractor never released (Group C)
Number of subjects: 60
Study 15071716 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 9
Study 15071716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of [(14)C]linezolid 500 mg (100-microCi)
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day regimen of unlabeled linezolid 500 mg b.i.d.
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: Single radioactive dose of linezolid
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142586 (T(max) of 3-5 h)
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142300 (T(max) of 2-3 h)
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid and PNU-142586 exposures at steady-state
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disposition of linezolid
Number of subjects: 15
Study 11454733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formation of PNU-142586
Number of subjects: 15
Study 9279247 — intervention group
Group type: EXPERIMENTAL
Intervention: RV16 (n = 19)
Number of subjects: 27
Study 9279247 — intervention group
Group type: COMPARATOR
Intervention: Diluent (Control, n = 8)
Number of subjects: 27
Study 7525901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 131I-iodized oil (Treated group)
Number of subjects: 27
Study 7525901 — intervention group
Group type: COMPARATOR
Intervention: Medical support (Control group)
Number of subjects: 27
Study 3596907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 31
Study 3596907 — intervention group
Group type: COMPARATOR
Intervention: No tranexamic acid (control)
Number of subjects: 31
Study 30014184 — intervention group
Group type: EXPERIMENTAL
Intervention: EG-1962 (600 mg)
Number of subjects: 0
Study 30014184 — intervention group
Group type: COMPARATOR
Intervention: Oral nimodipine (active control)
Number of subjects: 0
Study 26969198 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 703
Study 26969198 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 703
Study 25556905 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vertical overlap group
Number of subjects: 30
Study 25556905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 23980674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 1200
Study 23980674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 20830660 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-oriented inpatient rehabilitation program
Number of subjects: 302
Study 20830660 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group from the National Health Interview and Examination Survey for Children and Adolescents
Number of subjects: 302
Study 19119088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy (TT)
Number of subjects: 143
Study 19119088 — intervention group
Group type: COMPARATOR
Intervention: Near Total Thyroidectomy (NTT)
Number of subjects: 143
Study 16757502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressing
Number of subjects: 8
Study 15587331 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (EEN)
Number of subjects: 42
Study 15587331 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral hyperalimentation (TPN)
Number of subjects: 42
Study 11041466 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous fibrin sheath stripping (PFSS)
Number of subjects: 30
Study 11041466 — intervention group
Group type: COMPARATOR
Intervention: Over-the-wire catheter exchange (EX)
Number of subjects: 30
Study 9300476 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic perfusion (36 degrees C)
Number of subjects: 50
Study 9300476 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic perfusion (28 degrees C)
Number of subjects: 50
Study 8101150 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 50
Study 8101150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 50
Study 8101150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 50
Study 8101150 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg ondansetron
Number of subjects: 50
Study 8101150 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg ondansetron
Number of subjects: 50
Study 2873161 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine suspension (30 mg twice daily for children <30 kg; 60 mg twice daily for children >30 kg)
Number of subjects: 119
Study 2873161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 2873161 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine suspension
Number of subjects: 119
Study 3348158 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake
Number of subjects: 0
Study 30656507 — intervention group
Group type: COMPARATOR
Intervention: Model 1 (usual clinical variables)
Number of subjects: 173
Study 30656507 — intervention group
Group type: COMPARATOR
Intervention: Model 2 (lung and systemic inflammatory biomarkers)
Number of subjects: 173
Study 30656507 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 3 (combination of Models 1 and 2)
Number of subjects: 173
Study 29099102 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) at doses of 25 mg orally every 12 hours for 12 months
Number of subjects: 13
Study 29099102 — intervention group
Group type: COMPARATOR
Intervention: Placebo with corn starch
Number of subjects: 13
Study 26050073 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-controlled robotics-assisted treadmill exercise (FC-RATE)
Number of subjects: 20
Study 26050073 — intervention group
Group type: COMPARATOR
Intervention: Conventional robotics-assisted treadmill exercise (RATE)
Number of subjects: 20
Study 23537970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1721
Study 23537970 — intervention group
Group type: COMPARATOR
Intervention: Abciximab plus heparin
Number of subjects: 1721
Study 21813109 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/day)
Number of subjects: 20
Study 19785815 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin as a monotherapy
Number of subjects: 0
Study 19785815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide as a monotherapy
Number of subjects: 0
Study 19785815 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 0
Study 16716847 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve Steps (TS) treatment
Number of subjects: 453
Study 15525622 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with povidone-iodine (2.5 mg/mL, 25 mL)
Number of subjects: 38
Study 15525622 — intervention group
Group type: COMPARATOR
Intervention: Control group (gargling with tap water, 25 mL)
Number of subjects: 38
Study 11561930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline plus perphenazine
Number of subjects: 36
Study 11561930 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline plus placebo
Number of subjects: 36
Study 9428831 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 100 mg/day)
Number of subjects: 96
Study 9428831 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 x 850 mg/day)
Number of subjects: 96
Study 9428831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8296490 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel
Number of subjects: 14
Study 8296490 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and desogestrel
Number of subjects: 14
Study 8296490 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 14
Study 8296490 — intervention group
Group type: COMPARATOR
Intervention: 3-month washout period
Number of subjects: 14
Study 3329123 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose meal
Number of subjects: 10
Study 3329123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose meal
Number of subjects: 10
Study 3329123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose meal
Number of subjects: 10
Study 3329123 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk meal
Number of subjects: 10
Study 30150504 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth oral disinfection (FMD)
Number of subjects: 40
Study 30150504 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling and root planing (Q-SRP)
Number of subjects: 40
Study 26455907 — intervention group
Group type: EXPERIMENTAL
Intervention: r-tPA + resveratrol
Number of subjects: 0
Study 26455907 — intervention group
Group type: COMPARATOR
Intervention: r-tPA + placebo
Number of subjects: 0
Study 24833047 — intervention group
Group type: EXPERIMENTAL
Intervention: LARC script
Number of subjects: 800
Study 24833047 — intervention group
Group type: COMPARATOR
Intervention: Control (no LARC script)
Number of subjects: 800
Study 22057852 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg twice weekly (fasting)
Number of subjects: 36
Study 22057852 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg twice weekly (high-fat breakfast)
Number of subjects: 36
Study 22057852 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg twice weekly (normal breakfast)
Number of subjects: 36
Study 22057852 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (overall treatment)
Number of subjects: 36
Study 19953620 — intervention group
Group type: EXPERIMENTAL
Intervention: Blowing time ratio
Number of subjects: 0
Study 17234565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended readings by mediums
Number of subjects: 8
Study 17234565 — intervention group
Group type: COMPARATOR
Intervention: Control readings
Number of subjects: 8
Study 17234565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediums' reading choices
Number of subjects: 8
Study 15924807 — intervention group
Group type: EXPERIMENTAL
Intervention: indapamide + fosinopril (I + F, n = 151)
Number of subjects: 463
Study 15924807 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol + nitrendipine (A + N, n = 160)
Number of subjects: 463
Study 15924807 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol + nitrendipine + metformin (A + N + M, n = 152)
Number of subjects: 463
Study 15924807 — intervention group
Group type: COMPARATOR
Intervention: Comparison of I + F vs A + N
Number of subjects: 463
Study 15924807 — intervention group
Group type: COMPARATOR
Intervention: Comparison of A + N vs A + N + M
Number of subjects: 463
Study 11898874 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger blanching (frequent attacks, affecting nine or ten digits)
Number of subjects: 12907
Study 11898874 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger blanching (50 or more attacks in the past year)
Number of subjects: 12907
Study 11898874 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger blanching (nine to ten digits affected)
Number of subjects: 12907
Study 10193541 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN) started not later than 6 h after admission (group A)
Number of subjects: 28
Study 10193541 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (EN) started later than 24 h after admission (group B)
Number of subjects: 28
Study 7572772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Tsu San Li (St-36)
Number of subjects: 0
Study 7572772 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture point
Number of subjects: 0
Study 2299213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccines with increasing antigen concentrations
Number of subjects: 140
Study 7027780 — intervention group
Group type: EXPERIMENTAL
Intervention: High nutrition supplement (800 kcal and 40 g of protein/day)
Number of subjects: 294
Study 7027780 — intervention group
Group type: COMPARATOR
Intervention: Low nutrition supplement (80 kcal/day)
Number of subjects: 294
Study 31017305 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback intervention aimed at primary care centers, involving structured quality reports on medication use and diagnosis recording, sent in 2015.
Number of subjects: 12766
Study 31017305 — intervention group
Group type: COMPARATOR
Intervention: Control centers (no specific intervention).
Number of subjects: 12766
Study 29529508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) skills training
Number of subjects: 84
Study 29529508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance without judgment (as a dimension of mindfulness)
Number of subjects: 84
Study 29529508 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study 26881973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic renogram in volatile substance abusers
Number of subjects: 29
Study 26881973 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study 26357798 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (130/.42)
Number of subjects: 40
Study 26357798 — intervention group
Group type: COMPARATOR
Intervention: Gelatin
Number of subjects: 40
Study 22247115 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and organic acids (1 g/L in water) including Lactobacillus acidophilus, Lactobacillus casei, Streptococcus faecium, Saccharomyces cerevisiae, 1% sorbic acid, and 0.2% citric acid for 7 days (T2)
Number of subjects: 300
Study 22247115 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and organic acids (1 g/L in water) for 14 days (T3)
Number of subjects: 300
Study 22247115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics or organic acids, T1)
Number of subjects: 300
Study 19243831 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone
Number of subjects: 51
Study 19243831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phacotrabeculectomy with adjunctive mitomycin C
Number of subjects: 51
Study 17258092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17258092 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-microg low-dose (LD) UCN 2
Number of subjects: 8
Study 17258092 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-microg high-dose (HD) UCN 2
Number of subjects: 8
Study 15350324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical pupil dilatation with iris‐retractor hooks
Number of subjects: 40
Study 15350324 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate (PMMA) pupil dilator‐ring
Number of subjects: 40
Study 15350324 — intervention group
Group type: EXPERIMENTAL
Intervention: Beehler pupil dilator
Number of subjects: 40
Study 15350324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual stretching
Number of subjects: 40
Study 15350324 — intervention group
Group type: COMPARATOR
Intervention: Mechanical pupil dilatation methods (all groups)
Number of subjects: 40
Study 15350324 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris‐retractor hooks and PMMA pupil‐dilator ring
Number of subjects: 40
Study 15350324 — intervention group
Group type: COMPARATOR
Intervention: Comparison of added surgical time
Number of subjects: 40
Study 11429363 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prilocaine
Number of subjects: 60
Study 11429363 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 60
Study 9842626 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural hearing tactics treatment
Number of subjects: 63
Study 9842626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study 7857367 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin on a high fat diet (40% energy)
Number of subjects: 25
Study 7857367 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin on a low fat diet (22% energy)
Number of subjects: 25
Study 7857367 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin on a low fat diet
Number of subjects: 25
Study 7857367 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin with dietary fat reduction
Number of subjects: 25
Study 2678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogens monotherapy
Number of subjects: 0
Study 2678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with antiandrogens and castration
Number of subjects: 0
Study 2678684 — intervention group
Group type: COMPARATOR
Intervention: Castration alone
Number of subjects: 0
Study 1102567 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 9
Study 1102567 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1-mg dose)
Number of subjects: 9
Study 1102567 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 9
Study 31812918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated follow-up (PIFU) supported by a self-management approach
Number of subjects: 17
Study 31812918 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management approach
Number of subjects: 17
Study 31812918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated follow-up (PIFU)
Number of subjects: 17
Study 30982953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX) 3.28 μg kg-1
Number of subjects: 53
Study 30982953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX)
Number of subjects: 53
Study 28704880 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor cycling training at a local gym for 12 weeks, average 2.6 times per week
Number of subjects: 42
Study 28704880 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 42
Study 25277638 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus remifentanil (MR)
Number of subjects: 60
Study 25277638 — intervention group
Group type: COMPARATOR
Intervention: Morphine (M)
Number of subjects: 60
Study 23719683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rhPTH(1-31)NH2 tablets (5 mg)
Number of subjects: 32
Study 23719683 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous teriparatide (20 μg daily)
Number of subjects: 32
Study 23719683 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study 21767001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130
Study 21767001 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 130
Study 19512867 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (60 mg orally)
Number of subjects: 8
Study 19512867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (intravenous infusion to target plasma concentration of 0.6 ng/ml)
Number of subjects: 8
Study 19512867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of buspirone and dexmedetomidine
Number of subjects: 8
Study 19512867 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 8